Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof
AssigneeMedical Diagnostic Laboratories, LLC
InventorsGrant Gallagher, Raymond Yu, Jonathan Brazaitis
Life of this patent
Estimating the term…
Loading patent…
AssigneeMedical Diagnostic Laboratories, LLC
InventorsGrant Gallagher, Raymond Yu, Jonathan Brazaitis
Estimating the term…
The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.
An isolated polypeptide, said isolated polypeptide inhibits the binding of IL-23 to IL-23 receptor and the IL-23-mediated signaling, and said isolated polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:
An isolated polypeptide of 9-18 amino acids in length, said isolated polypeptide comprises a core structure that consists of an amino acid sequence of WVDYW (SEQ ID NO:
Dependencies are inferred from the claim text.